{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T08:52:13Z","timestamp":1781513533486,"version":"3.54.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP2027453"],"award-info":[{"award-number":["APP2027453"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP2027453"],"award-info":[{"award-number":["APP2027453"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP2027453"],"award-info":[{"award-number":["APP2027453"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP2027453"],"award-info":[{"award-number":["APP2027453"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"Department of Health | National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP2027453"],"award-info":[{"award-number":["APP2027453"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      To estimate the health and societal costs and health-related quality of life (HRQoL) impacts of X-linked retinitis pigmentosa (XLRP) caused by\n                      <jats:italic>RPGR<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Primary data were obtained from a clinical cohort of 9 patients with X-linked retinitis pigmentosa (XLRP) and 4\u00a0caregivers. Health-related quality of life (HRQoL) impacts for patients and carers are assessed using utility values derived from the Assessment of Quality of Life\u20138 Dimension (AQoL-8D) instrument. Lifetime costs associated with XLRP are estimated through microsimulation modelling. The model accounts for both societal and healthcare costs, capturing the economic burden on patients, caregivers and their spouses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Average AQoL-8D utility values for patients with XLRP are 0.57, slightly lower than other inherited retinal diseases and significantly (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05) below age and gender adjusted population norms of 0.81. HUI2 and HUI3 values were 0.81 and 0.75, respectively. Lifetime costs for XLRP were AUD 7.0\u2009m. Most costs (79%) were societal costs. Using a range of prevalence estimates, national annual costs are estimated to be between AUD 38.4\u2009m and AUD 49.7\u2009m.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>XLRP imposes a substantial burden on quality of life and generates high societal costs relative to direct healthcare costs, consistent with patterns observed in other IRDs. The results highlight the importance of incorporating societal costs into cost-effectiveness analyses when assessing new interventions for individuals with XLRP, including genetic testing and emerging gene therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41433-026-04532-y","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T13:51:15Z","timestamp":1779371475000},"page":"1302-1307","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The quality-of-life impacts and economic burden of X-linked retinitis pigmentosa caused by variants in RPGR"],"prefix":"10.1038","volume":"40","author":[{"given":"Deborah","family":"Schofield","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2103-6726","authenticated-orcid":false,"given":"Joshua","family":"Kraindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupendra N.","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Wall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liny","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dustin","family":"Hewett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorraine","family":"Villaret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6763-8119","authenticated-orcid":false,"given":"John R.","family":"Grigg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn V.","family":"Jamieson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"4532_CR1","doi-asserted-by":"publisher","first-page":"238","DOI":"10.2174\/138920211795860107","volume":"12","author":"S Ferrari","year":"2011","unstructured":"Ferrari S, Di Iorio E, Barbaro V, Ponzin D, Sorrentino FS, Parmeggiani F. Retinitis pigmentosa: genes and disease mechanisms. Curr Genomics. 2011;12:238\u201349.","journal-title":"Curr Genomics"},{"key":"4532_CR2","doi-asserted-by":"publisher","first-page":"a017392","DOI":"10.1101\/cshperspect.a017392","volume":"5","author":"WA Beltran","year":"2014","unstructured":"Beltran WA, Cideciyan AV, Lewin AS, Hauswirth WW, Jacobson SG, Aguirre GD. Gene augmentation for X-linked retinitis pigmentosa caused by mutations in RPGR. Cold Spring Harb Perspect Med. 2014;5:a017392.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"4532_CR3","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1073\/pnas.1817639116","volume":"116","author":"Q Zhang","year":"2019","unstructured":"Zhang Q, Giacalone JC, Searby C, Stone EM, Tucker BA, Sheffield VC. Disruption of RPGR protein interaction network is the common feature of RPGR missense variations that cause XLRP. Proc Natl Acad Sci USA. 2019;116:1353\u201360.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4532_CR4","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/aos.14662","volume":"99","author":"M Zada","year":"2021","unstructured":"Zada M, Cornish EE, Fraser CL, Jamieson RV, Grigg JR. Natural history and clinical biomarkers of progression in X-linked retinitis pigmentosa: a systematic review. Acta Ophthalmol. 2021;99:499\u2013510.","journal-title":"Acta Ophthalmol"},{"key":"4532_CR5","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1080\/21678707.2018.1444476","volume":"6","author":"C Martinez-Fernandez De La Camara","year":"2018","unstructured":"Martinez-Fernandez De La Camara C, Nanda A, Salvetti AP, Fischer MD, MacLaren RE. Gene therapy for the treatment of X-linked retinitis pigmentosa. Expert Opin Orphan Drugs. 2018;6:167\u201377.","journal-title":"Expert Opin Orphan Drugs"},{"key":"4532_CR6","doi-asserted-by":"publisher","first-page":"8232","DOI":"10.1167\/iovs.12-11025","volume":"53","author":"K Branham","year":"2012","unstructured":"Branham K, Othman M, Brumm M, Karoukis AJ, Atmaca-Sonmez P, Yashar BM, et al. Mutations in RPGR and RP2 account for 15% of males with simplex retinal degenerative disease. Invest Ophthalmol Vis Sci. 2012;53:8232\u20137.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4532_CR7","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1080\/13816810.2022.2109686","volume":"43","author":"LC Vinikoor-Imler","year":"2022","unstructured":"Vinikoor-Imler LC, Simpson C, Narayanan D, Abbasi S, Lally C. Prevalence of RPGR-mutated X-linked retinitis pigmentosa among males. Ophthalmic Genet. 2022;43:581\u20138.","journal-title":"Ophthalmic Genet"},{"key":"4532_CR8","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1167\/iovs.06-0971","volume":"48","author":"MA Sandberg","year":"2007","unstructured":"Sandberg MA, Rosner B, Weigel-DiFranco C, Dryja TP, Berson EL. Disease course of patients with X-linked retinitis pigmentosa due to RPGR gene mutations. Investig Ophthalmol Vis Sci. 2007;48:1298\u2013304.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"4532_CR9","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.jmoldx.2016.06.007","volume":"18","author":"J Li","year":"2016","unstructured":"Li J, Tang J, Feng Y, Xu M, Chen R, Zou X, et al. Improved diagnosis of inherited retinal dystrophies by high-fidelity PCR of ORF15 followed by next-generation sequencing. J Mol Diagnost. 2016;18:817\u201324.","journal-title":"J Mol Diagnost"},{"key":"4532_CR10","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jamaophthalmol.2022.6254","volume":"141","author":"L von Krusenstiern","year":"2023","unstructured":"von Krusenstiern L, Liu J, Liao E, Gow JA, Chen G, Ong T, et al. Changes in retinal sensitivity associated with cotoretigene toliparvovec in X-linked retinitis pigmentosa with RPGR gene variations. JAMA Ophthalmol. 2023;141:275\u201383.","journal-title":"JAMA Ophthalmol"},{"key":"4532_CR11","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1016\/j.ymthe.2017.05.004","volume":"25","author":"WA Beltran","year":"2017","unstructured":"Beltran WA, Cideciyan AV, Boye SE, Ye GJ, Iwabe S, Dufour VL, et al. Optimization of retinal gene therapy for X-linked retinitis pigmentosa due to RPGR mutations. Mol Ther. 2017;25:1866\u201380.","journal-title":"Mol Ther"},{"key":"4532_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s40123-022-00602-y","volume":"12","author":"V Mansouri","year":"2023","unstructured":"Mansouri V. X-linked retinitis pigmentosa gene therapy: preclinical aspects. Ophthalmol Ther. 2023;12:7\u201334.","journal-title":"Ophthalmol Ther"},{"key":"4532_CR13","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1001\/jamaophthalmol.2022.6436","volume":"141","author":"S Sengupta","year":"2023","unstructured":"Sengupta S. Perspectives on evolving gene therapy for X-linked retinitis pigmentosa. JAMA Ophthalmol. 2023;141:283\u20134.","journal-title":"JAMA Ophthalmol"},{"key":"4532_CR14","doi-asserted-by":"publisher","first-page":"565","DOI":"10.2147\/CEOR.S297287","volume":"13","author":"M Chivers","year":"2021","unstructured":"Chivers M, Li N, Pan F, Wieffer H, Slowik R, Leartsakulpanitch J. The burden of X-linked retinitis pigmentosa on patients and society: a narrative literature review. Clinicoecon Outcomes Res. 2021;13:565\u201372.","journal-title":"Clinicoecon Outcomes Res"},{"key":"4532_CR15","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s40273-021-01003-y","volume":"39","author":"SA Huygens","year":"2021","unstructured":"Huygens SA, Versteegh MM, Vegter S, Schouten LJ, Kanters TA. Methodological challenges in the economic evaluation of a gene therapy for RPE65-mediated inherited retinal disease: the value of vision. Pharmacoeconomics. 2021;39:383\u201397.","journal-title":"Pharmacoeconomics"},{"key":"4532_CR16","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2021.2002006","volume":"9","author":"M Pochopie\u0144","year":"2021","unstructured":"Pochopie\u0144 M, Paterak E, Clay E, Janik J, Aballea S, Biernikiewicz M, et al. An overview of health technology assessments of gene therapies with a focus on cost-effectiveness models. J Mark Access Health Policy. 2021;9:2002006.","journal-title":"J Mark Access Health Policy"},{"key":"4532_CR17","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jval.2024.08.009","volume":"28","author":"J Hitch","year":"2025","unstructured":"Hitch J, Denee T, Brassel S, Lee J, Michaelides M, Petersen J, et al. Challenges in value assessment for one-time gene therapies for inherited retinal diseases: are we turning a blind eye? Value Health. 2025;28:116\u201324.","journal-title":"Value Health"},{"key":"4532_CR18","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ajo.2017.02.016","volume":"177","author":"AE Chaumet-Riffaud","year":"2017","unstructured":"Chaumet-Riffaud AE, Chaumet-Riffaud P, Cariou A, Devisme C, Audo I, Sahel JA, et al. Impact of retinitis pigmentosa on quality of life, mental health, and employment among young adults. Am J Ophthalmol. 2017;177:169\u201374.","journal-title":"Am J Ophthalmol"},{"key":"4532_CR19","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s10384-021-00875-z","volume":"65","author":"D Altinbay","year":"2021","unstructured":"Altinbay D, Taskin I. Evaluation of vision-related quality of life in retinitis pigmentosa patients with low vision. Jpn J Ophthalmol. 2021;65:777\u201385.","journal-title":"Jpn J Ophthalmol"},{"key":"4532_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2021.100106","volume":"2","author":"D Schofield","year":"2022","unstructured":"Schofield D, Kraindler J, Tan O, Shrestha R, Jelovic D, West S, et al. Patient-reported health-related quality of life in individuals with inherited retinal diseases. Ophthalmol Sci. 2022;2:100106.","journal-title":"Ophthalmol Sci"},{"key":"4532_CR21","doi-asserted-by":"publisher","first-page":"e736","DOI":"10.1111\/aos.16634","volume":"102","author":"MB McGuinness","year":"2024","unstructured":"McGuinness MB, Ayton LN, Schofield D, Britten-Jones AC, Chen FK, Grigg JR, et al. EQ-5D-5L health utility scores in Australian adults with inherited retinal diseases: a cross-sectional survey. Acta Ophthalmol. 2024;102:e736\u2013e45.","journal-title":"Acta Ophthalmol"},{"key":"4532_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/IAE.0000000000003920","volume":"44","author":"BL Lam","year":"2024","unstructured":"Lam BL, Scholl HPN, Doub D, Sperling M, Hashim M, Li N. A systematic literature review of disease progression reported in RPGR -associated x-linked retinitis pigmentosa. Retina. 2024;44:1\u20139.","journal-title":"Retina"},{"key":"4532_CR23","doi-asserted-by":"crossref","unstructured":"Lam BL, Scholl HPN, Doub D, Sperling M, Hashim M, Li N A Systematic literature review of disease progression reported in RPGR-associated X-linked retinitis pigmentosa. Retina. 2024;44:1\u20139.","DOI":"10.1097\/IAE.0000000000003920"},{"key":"4532_CR24","doi-asserted-by":"crossref","unstructured":"Matza LS, Li N, Stewart KD, Hashim M, Denee T, Pan F, et al. Health state utilities associated with X-linked retinitis pigmentosa (XLRP). Eur J Health Econ 2025;26:1263\u201373.","DOI":"10.1007\/s10198-025-01761-y"},{"key":"4532_CR25","doi-asserted-by":"publisher","first-page":"707","DOI":"10.2147\/OPTH.S241928","volume":"14","author":"O Galvin","year":"2020","unstructured":"Galvin O, Chi G, Brady L, Hippert C, Del Valle Rubido M, Daly A, et al. The impact of inherited retinal diseases in the Republic of Ireland (ROI) and the United Kingdom (UK) from a cost-of-illness perspective. Clin Ophthalmol. 2020;14:707\u201319.","journal-title":"Clin Ophthalmol"},{"key":"4532_CR26","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.2147\/OPTH.S313719","volume":"15","author":"J Gong","year":"2021","unstructured":"Gong J, Cheung S, Fasso-Opie A, Galvin O, Moniz LS, Earle D, et al. The impact of inherited retinal diseases in the United States of America (US) and Canada from a cost-of-illness perspective. Clin Ophthalmol. 2021;15:2855\u201366.","journal-title":"Clin Ophthalmol"},{"key":"4532_CR27","doi-asserted-by":"publisher","first-page":"70","DOI":"10.5694\/mja2.51997","volume":"219","author":"D Schofield","year":"2023","unstructured":"Schofield D, Kraindler J, Tan O, Shrestha RN, West S, Hart N, et al. The health care and societal costs of inherited retinal diseases in Australia: a microsimulation modelling study. Med J Aust. 2023;219:70\u20136.","journal-title":"Med J Aust"},{"key":"4532_CR28","doi-asserted-by":"publisher","first-page":"3827","DOI":"10.1038\/s41433-023-02624-7","volume":"37","author":"J Chay","year":"2023","unstructured":"Chay J, Tang RWC, Tan TE, Chan CM, Mathur R, Lee BJH, et al. The economic burden of inherited retinal disease in Singapore: a prevalence-based cost-of-illness study. Eye. 2023;37:3827\u201333.","journal-title":"Eye"},{"key":"4532_CR29","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.2147\/OPTH.S365486","volume":"16","author":"N Cross","year":"2022","unstructured":"Cross N, van Steen C, Zegaoui Y, Satherley A, Angelillo L. Retinitis pigmentosa: burden of disease and current unmet needs. Clin Ophthalmol. 2022;16:1993\u20132010.","journal-title":"Clin Ophthalmol"},{"key":"4532_CR30","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s40271-013-0036-x","volume":"7","author":"J Richardson","year":"2014","unstructured":"Richardson J, Iezzi A, Khan MA, Maxwell A. Validity and reliability of the assessment of Quality of Life (AQoL)-8D multi-attribute utility instrument. Patient. 2014;7:85\u201396.","journal-title":"Patient"},{"key":"4532_CR31","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1007\/s11136-016-1337-z","volume":"25","author":"A Maxwell","year":"2016","unstructured":"Maxwell A, \u00d6zmen M, Iezzi A, Richardson J. Deriving population norms for the AQoL-6D and AQoL-8D multi-attribute utility instruments from web-based data. Qual Life Res. 2016;25:3209\u201319.","journal-title":"Qual Life Res"},{"key":"4532_CR32","unstructured":"Lambert S, Percival, R, Schofield, D, Paul, S. An introduction to STINMOD: a static microsimulation model. (STINMOD technical paper; No. 1). National Centre for Social and Economic Modelling (NATSEM). 1994."},{"key":"4532_CR33","unstructured":"Australian Bureau of Statistics. Life tables, 2019\u20132021 [Available from: https:\/\/www.abs.gov.au\/statistics\/people\/population\/life-tables\/2019-2021."},{"key":"4532_CR34","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/0002-9394(84)90636-6","volume":"97","author":"CH Bunker","year":"1984","unstructured":"Bunker CH, Berson EL, Bromley WC, Hayes RP, Roderick TH. Prevalence of retinitis pigmentosa in Maine. Am J Ophthalmol. 1984;97:357\u201365.","journal-title":"Am J Ophthalmol"},{"key":"4532_CR35","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.1167\/iovs.07-0071","volume":"48","author":"H Prokisch","year":"2007","unstructured":"Prokisch H, Hartig M, Hellinger R, Meitinger T, Rosenberg T. A population-based epidemiological and genetic study of X-linked retinitis pigmentosa. Investig Ophthalmol Vis Sci. 2007;48:4012\u20138.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"4532_CR36","unstructured":"Australian Bureau of Statistics. National, state and territory population 2024 [Available from: https:\/\/www.abs.gov.au\/statistics\/people\/population\/national-state-and-territory-population\/jun-2024."},{"key":"4532_CR37","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1080\/14728214.2022.2152003","volume":"27","author":"C Mart\u00ednez-Fern\u00e1ndez de la C\u00e1mara","year":"2022","unstructured":"Mart\u00ednez-Fern\u00e1ndez de la C\u00e1mara C, Cehajic-Kapetanovic J, MacLaren RE. Emerging gene therapy products for RPGR-associated X-linked retinitis pigmentosa. Expert Opin Emerg Drugs. 2022;27:431\u201343.","journal-title":"Expert Opin Emerg Drugs"},{"key":"4532_CR38","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.jval.2020.12.017","volume":"24","author":"LS Matza","year":"2021","unstructured":"Matza LS, Stewart KD, Lloyd AJ, Rowen D, Brazier JE. Vignette-based utilities: usefulness, limitations, and methodological recommendations. Value Health. 2021;24:812\u201321.","journal-title":"Value Health"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04532-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04532-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04532-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T07:54:40Z","timestamp":1781510080000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04532-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["4532"],"URL":"https:\/\/doi.org\/10.1038\/s41433-026-04532-y","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"assertion":[{"value":"15 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"John Grigg and Robyn Jamieson have received consultancy fees from Johnson and Johnson.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}